Literature DB >> 23423742

Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.

Sophie Caillard1, Raphael Porcher, François Provot, Jacques Dantal, Sylvain Choquet, Antoine Durrbach, Emmanuel Morelon, Valérie Moal, Benedicte Janbon, Eric Alamartine, Claire Pouteil Noble, Delphine Morel, Nassim Kamar, Matthias Buchler, Marie France Mamzer, Marie Noelle Peraldi, Christian Hiesse, Edith Renoult, Olivier Toupance, Jean Philippe Rerolle, Sylvie Delmas, Philippe Lang, Yvon Lebranchu, Anne Elisabeth Heng, Jean Michel Rebibou, Christiane Mousson, Denis Glotz, Joseph Rivalan, Antoine Thierry, Isabelle Etienne, Marie Christine Moal, Laetitia Albano, Jean François Subra, Nacera Ouali, Pierre François Westeel, Michel Delahousse, Robert Genin, Bruno Hurault de Ligny, Bruno Moulin.   

Abstract

PURPOSE: Post-transplantation lymphoproliferative disorder (PTLD) is associated with significant mortality in kidney transplant recipients. We conducted a prospective survey of the occurrence of PTLD in a French nationwide population of adult kidney recipients over 10 years. PATIENTS AND METHODS: A French registry was established to cover a nationwide population of transplant recipients and prospectively enroll all adult kidney recipients who developed PTLD between January 1, 1998, and December 31, 2007. Five hundred patient cases of PTLD were referred to the French registry. The prognostic factors for PTLD were investigated using Kaplan-Meier and Cox analyses.
RESULTS: Patients with PTLD had a 5-year survival rate of 53% and 10-year survival rate of 45%. Multivariable analyses revealed that age > 55 years, serum creatinine level > 133 μmol/L, elevated lactate dehydrogenase levels, disseminated lymphoma, brain localization, invasion of serous membranes, monomorphic PTLD, and T-cell PTLD were independent prognostic indicators of poor survival. Considering five variables at diagnosis (age, serum creatinine, lactate dehydrogenase, PTLD localization, and histology), we constructed a prognostic score that classified patients with PTLD as being at low, moderate, high, or very high risk for death. The 10-year survival rate was 85% for low-, 80% for moderate-, 56% for high-, and 0% for very high-risk recipients.
CONCLUSION: This nationwide study highlights the prognostic factors for PTLD and enables the development of a new prognostic score. After validation in an independent cohort, the use of this score should allow treatment strategies to be better tailored to individual patients in the future.

Entities:  

Mesh:

Year:  2013        PMID: 23423742     DOI: 10.1200/JCO.2012.43.2344

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  Infectious complications of immune modulatory agents.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

2.  Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.

Authors:  Nayoun Kim; Hyun-Jung Sohn; Joo Hyun Oh; Young-Woo Jeon; Hyun-Joo Lee; Hyun-Il Cho; Byung Ha Chung; Chul-Woo Yang; Tai-Gyu Kim; Seok-Goo Cho
Journal:  Int J Hematol       Date:  2017-11-29       Impact factor: 2.490

3.  The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.

Authors:  M R Luskin; D S Heil; K S Tan; S Choi; E A Stadtmauer; S J Schuster; D L Porter; R H Vonderheide; A Bagg; D F Heitjan; D E Tsai; R Reshef
Journal:  Am J Transplant       Date:  2015-05-18       Impact factor: 8.086

4.  Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Authors:  Aaron S Rosenberg; Andreas K Klein; Robin Ruthazer; Andrew M Evens
Journal:  Am J Hematol       Date:  2016-04-26       Impact factor: 10.047

Review 5.  Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.

Authors:  Fedaey Abbas; Mohsen El Kossi; Ihab Sakr Shaheen; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2020-02-28

6.  A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders.

Authors:  Sophie Caillard; Etienne Cellot; Jacques Dantal; Olivier Thaunat; François Provot; Bénédicte Janbon; Matthias Buchler; Dany Anglicheau; Pierre Merville; Philippe Lang; Luc Frimat; Charlotte Colosio; Eric Alamartine; Nassim Kamar; Anne Elisabeth Heng; Antoine Durrbach; Valérie Moal; Joseph Rivalan; Isabelle Etienne; Marie Noelle Peraldi; Anne Moreau; Bruno Moulin
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-17       Impact factor: 8.237

7.  18F-FDG PET/CT for the Diagnosis of Malignant and Infectious Complications After Solid Organ Transplantation.

Authors:  Nastassja Muller; Romain Kessler; Sophie Caillard; Eric Epailly; Fabrice Hubelé; Céline Heimburger; Izzie-Jacques Namer; Raoul Herbrecht; Cyrille Blondet; Alessio Imperiale
Journal:  Nucl Med Mol Imaging       Date:  2016-11-28

Review 8.  Malignancies after pediatric kidney transplantation: more than PTLD?

Authors:  Martin Mynarek; Kais Hussein; Hans H Kreipe; Britta Maecker-Kolhoff
Journal:  Pediatr Nephrol       Date:  2013-09-24       Impact factor: 3.714

9.  Monomorphic Post-transplant Lymphoproliferative Disorder After Kidney Transplantation and Hematopoietic Stem Cell Transplantation: Clinicopathological Characteristics, Treatments and Prognostic Factors.

Authors:  Li Fu; Jianlan Xie; Jun Lin; Jingshi Wang; Na Wei; Dayong Huang; Tingting Wang; Jing Shen; Xiaoge Zhou; Zhao Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2017-03-03       Impact factor: 0.900

10.  Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes.

Authors:  Yuhua Ru; Xiang Zhang; Tiemei Song; Yiyang Ding; Ziling Zhu; Yi Fan; Yang Xu; Aining Sun; Huiying Qiu; Zhengming Jin; Xiaowen Tang; Yue Han; Zhengzheng Fu; Suning Chen; Xiao Ma; Feng Chen; Jia Chen; Depei Wu
Journal:  Bone Marrow Transplant       Date:  2020-02-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.